Last updated on January 2016

A 52 week study to examine the efficacy, safety and tolerability trial of once daily, oral doses of an experimental drug as adjunctive to insulin therapy in patients with Type 1 Diabetes Mellitus


Brief description of study

A 52 week study to examine the efficacy, safety and tolerability trial of once daily, oral doses of an experimental drug as adjunctive to insulin therapy in patients with Type 1 Diabetes Mellitus

Detailed Study Description

A 52 week phase 3, randomized, double-blind, placebo-controlled, parallel-group, efficacy, safety and tolerability trial of once daily, oral doses of an experimental drug as adjunctive to insulin therapy over in patients with Type 1 Diabetes Mellitus.

Clinical Study Identifier: TX142465

.

Contact Investigators or Research Sites near you

Start Over

Please choose location

View all locations

Amy King

AMCR Institute, Inc.
Escondido, CA USA
  Connect »